Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing
Article 2025 en
Authors
HV
Hélène Vanacker
MB
Mehdi Brahmi
DP
Daniel Pissaloux
Abstract
1 min read
WERS reliably identifies actionable NTRK fusions, predominantly in five NMT subtypes, whereas NTRK fusions were rare and extremely rare in other sarcomas where their targetability remains unclear. Routine NTRK screening should prioritize tumors suspected of being NMT rather than being broadly applied.
Steven A. Lubitz, Jennifer A. Brody, Nathan A. Bihlmeyer, Carolina Roselli, Lu‐Chen Weng, Ingrid E. Christophersen, Álvaro Alonso, Eric Boerwinkle, Richard A. Gibbs, Joshua C. Bis, L. Adrienne Cupples, Peter J. Mohler, Deborah A. Nickerson, Donna M. Muzny, Marco Pérez, Bruce M. Psaty, Elsayed Z. Soliman, Nona Sotoodehnia, Kathryn L. Lunetta, Emelia Benjamin, Susan R. Heckbert, Dan E. Arking, Patrick T. Ellinor, Honghuang Lin
Alberto Cascón, Iñaki Comino‐Méndez, María Currás-Freixes, Aguirre A. de Cubas, Laura Contreras, Susan Richter, Mirko Peitzsch, Veronika Mančíková, Lucía Inglada‐Pérez, Andrés Pérez‐Barrios, María Calatayud, Sharona Azriel, Rosa Villar-Vicente, Javier Aller, Fernando Setién, Sebastián Morán, Juan F. Garcı́a, Ana Rio‐Machín, Rocío Letón, Álvaro Gómez-Graña, María Apellániz-Ruiz, Giovanna Roncador, Manel Esteller, Cristina Rodríguez‐Antona,
Discussion(0)
No comments yet. Be the first to comment.